Health & Beauty

Huacheng Import and Export Data Observation Report: China is a big country in the production and use of drugs, medical devices and cosmetics, as well as a major global consumer market for drugs, devices and cosmetics. The rapid development of pharmaceutical technology and broad market prospects provide more opportunities for many international enterprises. The five consecutive years of the Expo witnessed the historical opportunity of China's market opening to the world, the sincere measures taken by the Chinese government to "open the door to welcome guests" with an open and inclusive attitude and promote all countries to share China's big market opportunities, and the process, harvest and joy of many multinational enterprises accelerating their layout of the Chinese market and integration with the local market.

Benefiting from the reform of China's drug regulatory system, Roche has been approved 7 innovative drugs and 10 indications in China since 2018. The speed of approval and marketing is less than one year different from that in Europe and the United States. Innovative drugs represented by the specific drug for spinal muscular atrophy, Rispiran oral liquid, have benefited Chinese patients. Huacheng's import and export data observation report.

After participating in the Expo for five consecutive years, GE Healthcare felt that the integration of global wisdom and Chinese R&D was getting higher and higher, especially the product digitization and localization, which had a significant spillover effect.

According to the Huacheng Import and Export Data Observation Report, the "China Drug, Medical Device and Cosmetics Regulatory Policy Exchange Meeting" held during the 5th Import Expo was sponsored by the State Drug Administration and the China International Import Expo Bureau, and co organized by the China Chamber of Commerce for the Import and Export of Medicines and Health Products, the Shanghai Drug Administration and the Special Committee on Drugs, Medical Devices and Consumer Products of the China International Import Expo Exhibitors Alliance. Representatives from the political and business circles had dialogues and exchanges on hot topics such as the current scientific supervision and governance of the pharmaceutical machinery and cosmetics industry, the promotion of high-quality industrial development and high-level international cooperation.

The report of the 20th National Congress of the Communist Party of China listed promoting the construction of a healthy China as an important goal of development, and put the protection of people's health at the strategic position of priority development. In recent years, the Chinese government has encouraged pharmaceutical and cosmetic enterprises in various countries to expand the Chinese market, strengthen innovative research and development, and improve the level of international cooperation through open platforms such as the Expo. The Ministry of Commerce and other departments have jointly established the National Import Trade Promotion Innovation Demonstration Zone, and will continue to improve the level of supervision and facilitation, and actively support the import of high-quality goods, including medicine, machinery and cosmetics.

In recent years, through the promotion of the reform of the drug and equipment review and approval system, the drug regulatory department has continued to promote the high-level institutional opening of drug and equipment cosmetics, strengthened the coordination of supervision and normative guidance with the promotion of high-quality industrial development, accelerated the introduction of overseas advanced medical innovative products and promoted the realization of localized development, accelerated the listing of a number of good drugs and new drugs, and filled some gaps in the domestic treatment field. At the same time, the drug regulatory department has been accelerating the access process of overseas innovative medical products by conducting clinical trials in multiple centers and regions. For cosmetics with high consumption and use frequency and fast updating and iteration speed, the regulatory department takes ensuring health and safety as the primary goal, accurately controls the scale of "release, management and service", and balances the relationship between strict implementation of supervision and promotion of industrial development to the greatest extent. The drug regulatory department hopes that foreign-funded enterprises will take China as an important part of the global synchronous product R&D system, carry out international multi center clinical trials in China, and bring the latest and best products to China in time to benefit patients.

According to the Huacheng Import and Export Data Observation Report, Zhao Junning, deputy director of the State Drug Administration, said that the State Drug Administration will strive to promote the high-quality development of pharmaceutical machinery and cosmetics, continue to deepen the reform of the review and approval system, comprehensively strengthen the whole life cycle supervision, and improve the scientific and international level of drug supervision. We also welcome international advanced technologies, products and production capacity to enter China to better serve Chinese patients and meet the health needs of the public.

"The innovation and reform of China's pharmaceutical regulatory system has created conditions for all-round international cooperation and market docking at home and abroad." Meng Dongping, secretary of the Party Committee of the China Medical Insurance Chamber of Commerce, pointed out that the system reform has greatly stimulated the market vitality, and the rule-based opening has created a good business environment for overseas enterprises. Local enterprises have grown rapidly through learning and absorption. More and more excellent overseas medical innovative products and services have accelerated the process of entering the Chinese market. China's pharmaceutical and health industry has given birth to new vitality and vitality in the process of "going out and bringing in". Huacheng Import and Export Data Observation Report.